| Cardiovascular Risk Management |
1 |
1 |
| Obesity |
0 |
0.99 |
| Lipids Management |
0 |
0.68 |
| Heart Failure (HF) |
0 |
0.46 |
| Weight Loss |
0 |
0.44 |
| Weight Management |
0 |
0.4 |
| Adverse Effects |
0 |
0.35 |
| Heart |
0 |
0.35 |
| Statins |
0 |
0.35 |
| Patient Safety |
0 |
0.32 |
| Revenue and Practice Management |
0 |
0.32 |
| Cardiovascular Imaging |
0 |
0.27 |
| Blood |
0 |
0.26 |
| Primary Care |
0 |
0.26 |
| Beta-Adrenergic Agonist |
0 |
0.17 |
| Cardiovascular disease |
0 |
0.17 |
| Insurance |
0 |
0.17 |
| Nausea |
0 |
0.17 |
| Receptors |
0 |
0.17 |
| Social Determinants of Health |
0 |
0.16 |
| PCSK9 |
0 |
0.15 |
| LDL Cholesterol |
0 |
0.12 |
| Abdomen |
0 |
0.09 |
| ACE Inhibitor |
0 |
0.09 |
| Board Certification |
0 |
0.09 |
| Clinical Guidelines |
0 |
0.09 |
| Ejection Fraction |
0 |
0.09 |
| Endocrinology |
0 |
0.09 |
| Exercise |
0 |
0.09 |
| Financial Reimbursement |
0 |
0.09 |
| Gastroparesis |
0 |
0.09 |
| Generics |
0 |
0.09 |
| Grant |
0 |
0.09 |
| Health Equity |
0 |
0.09 |
| Infarction |
0 |
0.09 |
| Kidney |
0 |
0.09 |
| Lipoproteins |
0 |
0.09 |
| Medicare |
0 |
0.09 |
| Metabolism |
0 |
0.09 |
| New York |
0 |
0.09 |
| Orbit |
0 |
0.09 |
| Quality of Life |
0 |
0.09 |
| Salary and Compensation |
0 |
0.09 |
| Sleep |
0 |
0.09 |
| Cerebrovascular Accident |
0 |
0.08 |
| Myocardial Infarction (MI) |
0 |
0.08 |